What is William Blair’s Estimate for IONS FY2025 Earnings?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Stock analysts at William Blair increased their FY2025 EPS estimates for Ionis Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 21st. William Blair analyst M. Minter now expects that the company will earn ($3.60) per share for the year, up from their previous forecast of ($3.80). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.47) per share.

Several other research analysts have also recently weighed in on IONS. Piper Sandler reduced their price objective on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Wells Fargo & Company reduced their price target on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th. Needham & Company LLC reiterated a “buy” rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Guggenheim reduced their target price on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, October 9th. Finally, StockNews.com lowered shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Ionis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $60.65.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ IONS opened at $34.46 on Thursday. The company has a fifty day moving average price of $35.22 and a 200 day moving average price of $40.81. Ionis Pharmaceuticals has a 1-year low of $31.40 and a 1-year high of $52.49. The firm has a market cap of $5.44 billion, a PE ratio of -14.12 and a beta of 0.35. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Ionis Pharmaceuticals by 3.5% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,624 shares of the company’s stock worth $363,000 after purchasing an additional 261 shares in the last quarter. Nicollet Investment Management Inc. grew its stake in Ionis Pharmaceuticals by 1.5% during the third quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company’s stock worth $817,000 after buying an additional 294 shares in the last quarter. Amalgamated Bank increased its holdings in Ionis Pharmaceuticals by 3.1% in the 3rd quarter. Amalgamated Bank now owns 9,957 shares of the company’s stock valued at $399,000 after buying an additional 300 shares during the period. GAMMA Investing LLC raised its position in shares of Ionis Pharmaceuticals by 83.9% in the 3rd quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock valued at $27,000 after buying an additional 303 shares in the last quarter. Finally, Itau Unibanco Holding S.A. lifted its holdings in shares of Ionis Pharmaceuticals by 40.9% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company’s stock worth $43,000 after acquiring an additional 314 shares during the period. Institutional investors own 93.86% of the company’s stock.

Insider Activity

In other Ionis Pharmaceuticals news, EVP Eric Swayze sold 1,194 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total transaction of $45,276.48. Following the transaction, the executive vice president now owns 33,713 shares in the company, valued at $1,278,396.96. This represents a 3.42 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Brett P. Monia sold 6,630 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $38.05, for a total transaction of $252,271.50. Following the completion of the sale, the chief executive officer now owns 167,393 shares of the company’s stock, valued at approximately $6,369,303.65. The trade was a 3.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 57,293 shares of company stock valued at $1,914,820. 2.71% of the stock is owned by insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.